2nd Quarter - Report

AMERICAN CANCER SOCIETY CANCER ACTION NETWORK, INC. for AMERICAN CANCER SOCIETY CANCER ACTION NETWORK INC

Firm
Client
Income
—
Expenses
$1,720,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Issues relating to the tax treatment of nonprofits, including governance of nonprofit organizations.

LobbyistCovered position, as disclosed
ROSALIE ABBOTT —
GREGG HAIFLEY —
RACHEL MARCUS —
CAROLINE POWERS —
RICHARD WOODRUFF —

Contacted: SENATE; Labor, Dept of (DOL); U.S. Trade Representative (USTR); State, Dept of (DOS); Centers For Disease Control & Prevention (CDC); Environmental Protection Agency (EPA); Natl Institutes of Health (NIH); U.S. Agency for International Development (USAID); Centers For Medicare and Medicaid Services (CMS); White House Office; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Health Issues HCR

Issues relating to health disparities, childhood cancer, quality of life and palliative care, federal health care programs, genetic information, cancer, nutrition, tanning beds, skin cancer, and wellness, including: H.R.1676 & S.693, the Palliative Care and Hospice Education and Training Act; the Breast Density & Mammography Reporting Act; H.R.820 & S.292, Childhood Cancer STAR Act; and, H.R. 1231 & S. 456, the RACE for Children Act. In addition, the discussion draft of The Diagnostic Accuracy and Innovation Act; and H.R.772 and S.261, the Common Sense Nutrition Disclosure Act.

Contacted: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); SENATE; Food & Drug Administration (FDA); Environmental Protection Agency (EPA); U.S. Trade Representative (USTR); Labor, Dept of (DOL); Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Centers For Disease Control & Prevention (CDC); U.S. Agency for International Development (USAID); State, Dept of (DOS); White House Office

Bills named: S. 693 (115th), H.R. 1676 (115th), H.R. 1231 (115th), S. 292 (115th), S. 261 (115th), H.R. 820 (115th), S. 456 (115th), H.R. 772 (115th)

Medicare/Medicaid MMM

Issues relating to legislative and regulatory changes to the Affordable Care Act, including H.R. 1628, the American Health Care Act and the Better Care Reconciliation Act. Issues relating to implementation of legislative or regulatory changes to Medicare and Medicaid, including Medicare Part B drug reimbursement. Issues before CMS relating to Medicare payment for preventive screening, coordinated patient care, care planning; H.R.1017 & S.479, Removing Barriers to Colorectal Cancer Screening Act; issues relating to CMS-issued regulations pertaining to Medicare Part B reimbursement, regulations relating to the Medicare Access and CHIP Reauthorization Act of 2015.

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); U.S. Agency for International Development (USAID); Centers For Disease Control & Prevention (CDC); White House Office; State, Dept of (DOS); Environmental Protection Agency (EPA); U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); Labor, Dept of (DOL)

Bills named: H.R. 1017 (115th), H.R. 1628 (115th), S. 479 (115th)

Budget/Appropriations BUD

Federal budget and appropriations for cancer research and programs, including: FY 2017 and FY 2018 federal appropriations for NIH, NCI, CDC, FDA; the Prevention & Public Health Fund, including the Labor-HHS-Education Appropriations Act and the Agriculture-FDA Appropriations Act. Also, issues relating to non-communicable diseases with respect to the FY18 State/Foreign Operations Appropriations Act.

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; White House Office; SENATE; Labor, Dept of (DOL); Natl Institutes of Health (NIH); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); U.S. Agency for International Development (USAID); State, Dept of (DOS); Centers For Disease Control & Prevention (CDC); U.S. Trade Representative (USTR); Environmental Protection Agency (EPA)

Tobacco TOB

Issues relating to smoking cessation, tobacco sales to minors, tobacco taxes, minimum smoking age, graphic warning labels, product regulation, and smokefree environments, including: implementation of the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31), including the proposed FDA deeming regulations. Issues relating to proposed FDA regulation of electronic cigarettes and/or cigars; H.R.564 & S.294, Traditional Cigar Manufacturing and Small Business Jobs Preservation Act; H.R. 1136, FDA Deeming Authorization Clarification Act. Issues related to FDA tobacco control, as considered in House and Senate, FY17 Agriculture Appropriations legislation and Labor, Health and Human Services Appropriations legislation.

Contacted: Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); U.S. Trade Representative (USTR); State, Dept of (DOS); Natl Institutes of Health (NIH); White House Office; Labor, Dept of (DOL); SENATE; Environmental Protection Agency (EPA); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; U.S. Agency for International Development (USAID)

Bills named: H.R. 1136 (115th), H.R. 564 (115th), S. 294 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.